Randomized parallel controlled trial of "on demand" therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease.

Randomized parallel controlled trial of "on demand" therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease. - Randomized parallel controlled trial of refiux esophagitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001937

Enrollment

200

Registered

2009-05-02

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease (LA gradeM or more)

Interventions

&quot

on demand&quot

therapy of omepral 20mg for 24 weeks continuous therapy of omepral 20mg for 24 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients had been classified into grade LA M, A, B, C, and D by endoscopy before initial treatment and whose endoscopic diagnosis was LA M and more after 8-weeks initial treatment. 2) Patients from who written informed consent was obtained.

Exclusion criteria

Exclusion criteria: 1) Patients who suffer from cancer. 2) Patients who suffer from serious liver disease, kidney disease, heart disease, or Haematological disorder 3) Patients who had the past of irritability for omeprazole 4) Pregnant women and patienst while suckling, and patients who have been hoping for pregnancy for the trial period. 5) Patients who participated in other clinical trials which are thought to influence to the result of this trial within one month before the start of the trial. 6) Patients who refuse endoscopic examination. 7) Patients who suffer from gastric ulcers and/or duodenal ulcers 8) Patients who are judged inappropriate for the clinical trial by doctors.

Design outcomes

Primary

Measure	Time frame
Amount of change of GOS score between before and after treatment Amount of change of QULRAS-J score between before and after treatment	—

Secondary

Measure	Time frame
Examination according to symptoms Evaluation of safety	—

Countries

Japan

Contacts

Public ContactAkihito Nagahara

Juntendo University School of Medicine Gastroenterology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Randomized parallel controlled trial of &quot;on demand&quot; therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease.